![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, July 06, 2016 5:10:43 PM
They also like to use their own time frames to measure ones investment and the time frames always come out as a loss.
Almost any time frame you use will show a loss. Only those who bought last summer, or many, many years ago shortly after NNVC was listed, can show a gain. So if anybody can be accused of cherry picking their time frame it's the people bragging about their gains.
Well the long cabal is now in charge!
That's hilarious. Only a couple years ago $2 was the floor that the bulls were confident NNVC would not go below. When we get to $4 I'll believe that the long cabal is now in charge. You say no one is selling the stock but then you insist that shorts are busy selling the stock.
I didn't invest because I was told by many individuals that 'you better wait until NNVC can prove that they can make this stuff in commercial qty's.' I researched and concluded the same.
Then why did you buy? NNVC still can't make commercial quantities. According to NNVC's latest SEC filing NNVC still can't make 500g quantities of any 'cide. And even if they could, 500g might be adequate for testing but still isn't commercial quantities.
I will bet they are on Big Pharma radar now, after they proved scale up. Don't be surprised if a deal is already mapped out waiting for the university results. This is a technology all big Pharma companies know they have to get in early or they will lose it to a competitor. I wouldn't be surprised if three or four companies have deals drawn up right now.
Ha ha ha ha ha ha!
Big pharma won't touch this stock with a 20 foot pole before successful phase II results on humans come out. And then they will bid for Theracour, which owns all the IP, not for NNVC.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM